Cite
HARVARD Citation
Beatch, G. et al. (2017). Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia–Pacific Region: A Phase 3 Randomized Controlled Trial. Journal of cardiovascular pharmacology. 69 (2), pp. 86-92. [Online].